Memorial Sloan Kettering interventional radiologist Constantinos T. Sofocleous

Constantinos T. Sofocleous, MD, PhD

Interventional Radiologist

My Role at MSK

Areas of Expertise

My Specialties

  • Interventional Oncology
  • Interventional Radiology
  • Image-Guided Therapies

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.
English
Share

About Me

What I Do at MSK
  • Attending Radiologist
Get To Know Me

I am an interventional radiologist specializing in interventional oncology, caring for people with cancer. I have been practicing interventional radiology since 1998 and joined the Interventional Radiology Service at Memorial Sloan Kettering in 2002. As an expert in interventional oncology, I use minimally invasive, image-guided procedures to diagnose and treat patients with cancer with minimal side effects, complications, and discomfort.

Read more

My expertise include the treatment of primary and metastatic liver and lung cancers using thermal ablation (radiofrequency, microwave, cryoablation) or other non-thermal sources of energy (NanoKnife ® or irreversible electroporation). I also specialize in catheter-directed therapies that treat malignant liver tumors that cannot be removed through surgery or destroyed locally (ablation). These treatments include embolization techniques that use beads alone or combined with chemotherapy or radiotherapy delivered directly into liver tumors. These beads combine the therapeutic effects of radiation (radio embolization or selective internal radiation therapy) or chemotherapy (DEB-TACE or chemoembolization) with that of small particle tumor microvasculature embolization. These approaches offer the best therapeutic option to people with cancer who are not candidates for surgery or ablation.

I lecture nationally and internationally on topics such as embolization, radio embolization, and ablation of liver tumors — particularly metastases from colorectal, breast, or other primary cancers as well as hepatocellular cancer. I have also lectured extensively on ablation as a treatment for primary and metastatic lung cancers.

I am involved in several multidisciplinary clinical, research, and educational activities at MSK. As a faculty member on the hepatobiliary, colorectal, and solid-tumor teams, I work very closely with a team of hepatobiliary, colon, and thoracic surgeons; gastrointestinal, breast, and other oncologists; and gastroenterologists and radiation therapists to determine the most appropriate treatment for patients with primary and metastatic cancer of the liver and lung. I am also a current member of the Institutional Review Board, which is responsible for reviewing all human subjects’ related research and monitoring ongoing research conducted at MSK to ensure compliance with regulations. 

My research interest is the assessment, validation, and development of biomarkers and surrogate imaging biomarkers. These can predict outcomes and help stratify patients undergoing ablation and imaging-guided locoregional therapies of tumors in general, and particularly in colon cancer metastases. I have published extensively on the treatment of colorectal, neuroendocrine, and breast cancer liver metastases treated by image-guided therapies including radiofrequency and microwave ablation, irreversible electroporation, small particle bland embolization, and radio embolization or selective internal radiation therapy with Yttrium 90 microspheres. I have also studied and published on the cellullar effects of ablation on liver tumors, the use of embolization to salvage infusion pumps in patients with colon cancer metastatic to the liver, and the use of drug eluding beads (DEB-TACE) to treat primary liver cancer. Currently, I am the MSK site primary investigator, along with medical oncologist Andrea Cercek, of a new multi-institutional, randomized controlled trial where we assess the value of treating people with colorectal cancer liver metastases with Yttrium 90 glass microspheres in addition to standard of care second-line chemotherapy. I am also the primary investigator of an ongoing study examining tissue before and after thermal ablation of colon cancer liver metastases to detect predictive biomarkers that can impact treatment outcomes. This study was initially supported through an NIH R21 grant and showed that biopsies after radiofrequency ablation can predict outcomes.

Despite my strong interest in research, my main focus remains caring for patients. Every cancer has a unique identity, so treatment must be tailored to each patient and each situation. The environment and philosophy of MSK allow me and my partners in interventional oncology and image-guided therapies to offer each patient the best possible care for their cancer. The combination of excellence in clinical work and research also allows us to design important and pivotal clinical trials that directly translate in the best patient care.

My Role at MSK

An interventional (IN-ter-VEN-shun-al) radiologist is a doctor with special training in using image-guided procedures to diagnose and treat disease.

Areas of Expertise

My Specialties

  • Interventional Oncology
  • Interventional Radiology
  • Image-Guided Therapies
Education & Honors

Education

  • MD, PhD, University of Athens School of Medicine (Greece)

Residencies

  • St. Luke's-Roosevelt Hospital Center
  • Columbia University College of Physicians and Surgeons

Awards and Honors

  • Castle Connolly: America’s Top Doctor (2024)
  • Top Doctors New York Metro Area, Castle Connolly (2023)
  • Castle Connolly: America's Top Doctors (2023)
  • Radiological Society of North America Interventional Radiology Research Trainee Prize (1997)
  • Roentgen Resident Research Award (1998)
  • Fellow, Society of Interventional Radiology (2005)
  • Fellow, Cardiovascular and Interventional Radiological Society of Europe (2013)

Fellowships

  • NYU Medical Center

Board Certifications

  • Radiology
  • CAQ Vascular and Interventional Radiology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

MSK has a tentative agreement with Cigna to continue coverage in 2024.

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor’s office. If you aren’t registered for MyMSK, call 646-227-2593 for your Enrollment ID.

Contact and Location

Dr. Sofocleous sees patients at one location.

Office Phone
Location
New York, NY

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Interventional Radiology Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

View Dr. Sofocleous's Lab

Publications on PubMed

Visit PubMed for a full listing of Dr. Sofocleous’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Constantinos T. Sofocleous discloses the following relationships and financial interests:

  • Medtronic
    Professional Services and Activities
  • NeuWave Medical, Inc
    Professional Services and Activities
  • Terumo Medical Corporation
    Professional Services and Activities
  • Varian Medical Systems
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures